OpenNashPodcasts

Person

Aris Baras

Aris Baras is a doctor who leads the Regeneron Genetics Center, and this page collects what he said on the Business of Biotech podcast about using genetics to discover new medicines. He told the show that only about 10 percent of the roughly 20,000 human genes had ever been pursued as drug targets, and that the drug industry has about a 90 percent failure rate.

He also described Regeneron's work with UK Biobank on a 500,000-person sequencing project, and said Regeneron has turned about 50 of more than 100 protective genetic discoveries into new medicines in its pipeline. Other topics include fatty liver disease, the use of AI to improve variant calling, and Regeneron's goal of sequencing 50 to 100 million people.

1 episodes · 18 quoted claims

Aris Baras says Regeneron's analysis found that only about 10 percent of the roughly 20,000 human genes had ever been pursued as drug targets.

“There's 20 ,000 genes, and we'd only been able to really go after about 10%.”

Business Of Biotech · 0:07:33

Aris Baras says the drug industry has about a 90 percent failure rate.

“that's why our industry has a 90 % failure rate, right? I mean, most people don't appreciate that.”

Business Of Biotech · 0:07:33

Aris Baras says Dallas Heart Study participants with loss-of-function PCSK9 variants had 90 percent lower rates of heart attacks and very low bad cholesterol.

“And those people had 90 % lower rates of heart attacks and very low levels of bad cholesterol.”

Business Of Biotech · 0:08:36

Regeneron Genetics Center scientists call people with genetics that protect them from disease "superhumans."

“We look for these superhumans, right? We call them superhumans, the ones that have these genetics that protect them from certain diseases.”

Business Of Biotech · 0:10:25

Aris Baras says Regeneron has turned about 50 of the over 100 protective genetic discoveries into new medicines in its pipeline.

“We've taken about half of them or so, maybe 50, and turned them into new medicines over a decade now into Regeneron's pipeline.”

Business Of Biotech · 0:11:20

Aris Baras says the protective PCSK9 variant is 10 to 100 times more common in African-Americans than in other groups.

“So that protective human genetics mutation in PCSK9, I forget the exact number, 10 times, 100 times more common in African-Americans than in every other type of person.”

Business Of Biotech · 0:13:02

Aris Baras says Regeneron aspires to sequence 50 to 100 million people and must rethink how it collects data to do so.

“We're actually aspiring to get to 50 or 100 million. And now we have to rethink how we do this.”

Business Of Biotech · 0:17:45

Aris Baras says genes make up only about 1 to 2 percent of the roughly 3 billion base pairs in the human genome.

“your genes are actually only about one or 2 % of your entire genome, right? Those 3 billion base pairs, it's maybe 30 to 60 million of those base pairs, right?”

Business Of Biotech · 0:21:41

Regeneron ran a 50,000-person proteomics pilot with UK Biobank and is extending protein measurement to all 500,000 participants.

“we do a 50 ,000 person proteomics study. Now we're completing that a couple of years later and doing everyone, all 500 ,000 in UK Biobank”

Business Of Biotech · 0:25:26

Regeneron worked with Sir Rory Collins and his UK Biobank team on a 500,000-person sequencing project.

“we work with the UK, you know, the amazing Sir Rory Collins and his team there. Same team that we did the 500 ,000, largest study ever in genetics, 500 ,000 person sequencing project.”

Business Of Biotech · 0:24:52

Collaborating with consumer genetics companies during COVID, Regeneron found genetic factors tied to severe COVID and hospitalization, and also protective factors, and published them.

“We found important genetic factors that could really put you at really high risk of getting severe COVID and hospitalizations.”

Business Of Biotech · 0:30:56

Aris Baras says tokenization lets consented participants be linked to health records through a de-identified code.

“Once you get people's consent to join these studies, you create a token, right?”

Business Of Biotech · 0:32:32

Aris Baras says it took about two and a half years from first patient dosed to approval for Regeneron's hearing-loss gene therapy.

“it was only two and a half years from the first patient dosed to getting that approval for me it's kind of a once in a career type of experience”

Business Of Biotech · 0:36:07

Aris Baras says excess liver fat leads to inflammation, fibrosis and ultimately liver failure, which is why a gene whose loss lowers liver fat was a target.

“Fat in the liver can be a very bad thing. It leads to inflammation, fibrosis, ultimately liver failure.”

Business Of Biotech · 0:38:05

Aris Baras says fatty liver disease has been a graveyard for drug development but is breaking through with approvals including Madrigal's.

“It's been a graveyard of drug development, but finally breaking through recently with Madrigal and others getting approvals in this space.”

Business Of Biotech · 0:39:03

Regeneron, in partnership with Alnylam, has a late-stage siRNA drug designed to silence a liver-fat gene pronounced "side B."

“And we've got an sRNA in late stage development that's designed to silence and turn off side B.”

Business Of Biotech · 0:40:19

Aris Baras says Regeneron uses AI to improve variant calling, deciding which genetic changes are important.

“So we use AI, for example, to train and learn and help us be more accurate when we say, hey, this variant is important. It's called variant calling.”

Business Of Biotech · 0:42:54

Aris Baras says Merck donated over $2 billion over many years to its ivermectin program against river blindness.

“Merck donated something like over $2 billion over many, many years to continue donating and supporting that program.”

Business Of Biotech · 0:50:25